neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Company profile
Ticker
NEXI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NEXI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
8-K
Departure of Directors or Certain Officers
5 Apr 24
NT 10-K
Notice of late annual filing
29 Mar 24
DEFA14A
Additional proxy soliciting materials
6 Feb 24
8-K
NexImmune Announces $3.67 Million
5 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
8-K
Termination of a Material Definitive Agreement
2 Feb 24
8-K
Other Events
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
DEFA14A
Additional proxy soliciting materials
18 Jan 24
Latest ownership filings
3
Albert N Marchio II
10 Apr 24
144/A
Notice of proposed sale of securities (amended)
22 Nov 23
144/A
Notice of proposed sale of securities (amended)
22 Nov 23
4
Alan S. Roemer
22 Nov 23
144
Notice of proposed sale of securities
21 Nov 23
3
TIMOTHY STOVER
8 Sep 23
4
Grant Verstandig
7 Jul 23
4
Leena Gandhi
7 Jul 23
4
Zhengbin Yao
7 Jul 23
4
Alan S. Roemer
7 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.06 mm | 9.06 mm | 9.06 mm | 9.06 mm | 9.06 mm | 9.06 mm |
Cash burn (monthly) | 2.43 mm | 3.08 mm | 3.33 mm | 3.74 mm | 2.43 mm | 3.06 mm |
Cash used (since last report) | 16.06 mm | 20.35 mm | 22.04 mm | 24.73 mm | 16.06 mm | 20.25 mm |
Cash remaining | -7.00 mm | -11.29 mm | -12.99 mm | -15.67 mm | -7.01 mm | -11.19 mm |
Runway (months of cash) | -2.9 | -3.7 | -3.9 | -4.2 | -2.9 | -3.7 |
Institutional ownership, Q2 2023
61.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 4 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.23 bn |
Total shares | 8.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
B&S NexImmune Holdco | 1.54 mm | $0.00 |
Piedmont Capital Partners | 1.38 mm | $0.00 |
Artal International S.C.A. | 1.20 mm | $0.00 |
Slate Path Capital | 925.00 k | $260.67 mm |
Adage Capital Partners GP, L.L.C. | 801.37 k | $225.83 mm |
Allen Operations | 635.93 k | $179.33 mm |
EPIQ Capital | 390.60 k | $110.07 mm |
Raymond James & Associates | 320.62 k | $90.35 mm |
PNC PNC Financial Services | 316.04 k | $89.12 mm |
First Manhattan | 149.11 k | $42.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Nov 23 | Alan S. Roemer | Common Stock | Sell | Dispose S | No | No | 1.9434 | 3,992 | 7.76 k | 0 |
21 Nov 23 | Alan S. Roemer | Common Stock | Sell | Dispose S | No | No | 2.1621 | 3,833 | 8.29 k | 3,992 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 12,634 | 20.72 k | 12,634 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.42 | 12,634 | 30.57 k | 0 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 23,122 | 37.92 k | 23,122 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.31 | 23,122 | 99.66 k | 0 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 9,556 | 15.67 k | 9,556 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17 | 9,556 | 162.45 k | 0 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 61,678 | 101.15 k | 61,678 |
4 Apr 23 | Paul D'Angio | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.82 | 61,678 | 112.25 k | 0 |
News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
NexImmune Has Received A Decision To Grant European Patent Number EP3970748 Titled "Nanoparticle Compositions And Methods For Immunotherapy"
20 Feb 24
12 Health Care Stocks Moving In Monday's After-Market Session
19 Feb 24
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
5 Feb 24
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
5 Feb 24